Zilver PTX drug-eluting stent selected as a top emerging health technology in Canada

Zilver PTX
Zilver PTX

The Canadian Network for Environmental Scanning in Health (CNESH) has selected Cook Medical’s Zilver PTX drug-eluting peripheral stent as a top 10 game-changing health technology for 2014. 

The CNESH top 10 list is designed to encourage the adoption and use of effective, safe health technologies in Canada and was announced at the 2014 Canadian Agency for Drugs and Technologies in Health (CADTH) symposium.

Zilver PTX is the first self-expanding, drug-eluting stent available to help treat peripheral arterial disease in the superficial femoral artery in Canada. Approximately 800,000 Canadians have peripheral artery disease. According to CADTH, the disease occurs in 4% of Canadians older than 40, increasing to 20% in individuals over the age of 75. Worldwide, recent reports have shown that has reached epidemic levels in developed countries, with 38 million new cases reported in the last 10 years.

“Now that we have over four years of clinical data showing a long-term drug effect compared to uncoated stents, the advantage of treating superficial femoral artery blockages with drug-eluting stents is clear,” said Mark Breedlove, vice president and global leader of Cook Medical’s Peripheral Intervention division. “It is fantastic to see CNESH highlight technologies that positively impact patient outcomes and healthcare costs by reducing the number of repeat procedures.”

Zilver PTX entered the European market in August 2009, the US market in November 2012, and is the first drug-eluting stent indicated to treat peripheral arterial disease in the superficial femoral artery in Canada. Since its release, the stent has been used to treat more than 25,000 patients in Europe, Asia, South America, Australia, New Zealand and India.